KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Cash & Current Investments data on record, last reported at $5.1 billion in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 16.86% year-over-year to $5.1 billion; the TTM value through Dec 2025 reached $5.1 billion, down 16.86%, while the annual FY2025 figure was $5.1 billion, 16.86% down from the prior year.
  • Cash & Current Investments reached $5.1 billion in Q4 2025 per VRTX's latest filing, up from $4.9 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $11.9 billion in Q3 2023 and bottomed at $1.5 billion in Q1 2025.
  • Average Cash & Current Investments over 5 years is $8.0 billion, with a median of $7.5 billion recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: soared 65.23% in 2021, then crashed 85.01% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $7.5 billion in 2021, then soared by 43.14% to $10.8 billion in 2022, then grew by 4.08% to $11.2 billion in 2023, then crashed by 45.48% to $6.1 billion in 2024, then dropped by 16.86% to $5.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $5.1 billion in Q4 2025, $4.9 billion in Q3 2025, and $1.5 billion in Q1 2025.